Executives Depart Cassava, Maker of Disputed Alzheimer’s Drug

Executives Depart Cassava, Maker of Disputed Alzheimer’s Drug

The chief executive and a lead scientist stepped down weeks after a federal grand jury filed fraud charges against a research collaborator. The chief executive and a lead scientist stepped down weeks after a federal grand jury filed fraud charges against a research collaborator. your-feed-science, Appointments and Executive Changes, Drugs (Pharmaceuticals), Clinical Trials, Alzheimer’s Disease, Falsification of Data, Research, Academic and Scientific Journals, Securities and Commodities Violations, Cassava Sciences Inc, City College of New York NYT > Science

Leave a Reply

Your email address will not be published. Required fields are marked *